Acción TTI THIOGENESIS THERAPEUTICS, CORP.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Thiogenesis Therapeutics, Corp.

Acciones

TTI

CA88410L1022

Mercado cerrado - Toronto S.E.
Otros sitios de cotización
 15:47:11 14/06/2024 		Varia. Cinco días. Varia. 1 de enero.
0,7 CAD -2,78 % Gráfico intradía de Thiogenesis Therapeutics, Corp. 0,00 % -6,67 %
24/05 Thiogenesis Therapeutics, Corp. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
29/04 Thiogenesis Therapeutics, Corp. informa de los resultados del ejercicio finalizado el 31 de diciembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Thiogenesis Therapeutics, Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Thiogenesis Therapeutics, Corp. Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS
Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS
Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement
Thiogenesis Therapeutics, Corp. announced that it has received CAD 4.500875 million in funding
Thiogenesis Therapeutics Completes Non-Brokered Private Placement
Thiogenesis Announces Closing of Non-Brokered Private Placement of Common Shares and Insider Participation
Thiogenesis Therapeutics, Corp. announces tranche update
Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria Symposium
Thiogenesis Therapeutics, Corp. Announces Appointment of Vincent Stanton Jr. to the Scientific Advisory Board
Thiogenesis Announces Addition of Dr. Vince Stanton Jr. to Its Scientific Advisory Board
Thiogenesis Announces Non-Brokered Private Placement of Common Shares
Thiogenesis Therapeutics, Corp. announced that it expects to receive CAD 4.5 million in funding
Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Thiogenesis Therapeutics, Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
Thiogenesis Therapeutics Completes Oversubscribed $5.3 Million Non-Brokered Private Placement
Thiogenesis Therapeutics, Corp. announced that it has received CAD 5.3097 million in funding
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción TTI
  4. Noticias Thiogenesis Therapeutics, Corp.
  5. Otros idiomas